Vincerx Pharma Inc (NASDAQ: VINC) shares are trading higher after the company released clinical results from a Phase 1 NIH-sponsored study of enitociclib in combination with venetoclax and prednisone for
Investigators from the National Institutes of Health report 2 partial responses in 3 peripheral T-cell lymphoma patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma patients in ongoing.
Coral restoration programs are up against long odds because of climate change and environmental degradation, but marine scientists say they are critical for ensuring that certain species of coral do not become extinct.